NPM1 mutation with DNMT3A wild type defines a subgroup of MDS with particularly favourable outcomes after decitabine therapy.
Lingyun WuLing-Yun WuFeng XuDong WuQi HeLuxi SongChao XiaoYoushan ZhaoZheng ZhangJuan GuoLiyu ZhouJiying SuChunkang ChangPublished in: British journal of haematology (2020)